TransThera Sciences (Nanjing), Inc. (2617)

Overview

TransThera Sciences (Nanjing), Inc. is a clinical-stage biopharmaceutical company operating out of Nanjing, China. The company specializes in the discovery and development of innovative small molecule therapies aimed at addressing significant unmet medical needs in various therapeutic areas, including oncology, inflammatory diseases, and cardiometabolic conditions. TransThera operates with a fully integrated in-house research and development system, enabling it to advance its drug candidates efficiently and effectively.

The company's leading product is Tinengotinib (TT-00420), a unique multi-targeted kinase inhibitor designed to target critical pathways involved in the proliferation and survival of cancer cells. Tinengotinib is currently undergoing pivotal registrational clinical trials for treating cholangiocarcinoma, specifically in patients who have previously received FGFR inhibitor therapy. One of these trials is being conducted within China, showcasing the company's commitment to addressing regional healthcare needs. Additionally, TransThera Sciences is expanding its pipeline with five clinical-stage candidates and a preclinical asset, such as TT-00434 and TT-00920, underscoring its focus on enhancing tumor response and immune system modulation.

Products and Services

• Tinengotinib (TT-00420)

  A multi-targeted kinase inhibitor currently in two pivotal registrational clinical trials for the treatment of cholangiocarcinoma, particularly in patients who have undergone prior FGFR inhibitor therapy. Its novel mechanisms target essential pathways involved in cancer progression, providing a potential new treatment option for patients with this challenging condition.

• TT-00434

  This clinical-stage candidate is under development with a focus on enhancing therapeutic efficacy in oncology. Its specific mechanisms target critical pathways to improve tumor responses, offering new hope for patients with hard-to-treat cancers.

• TT-00920

  This investigational compound is designed to modulate immune responses in tumor settings, potentially amplifying the body’s ability to fight cancer. Its development aims to bridge the gap between tumor biology and immune system engagement, a critical aspect of modern cancer therapy.

• Pipeline Candidates

  In addition to the aforementioned products, TransThera is actively developing several other clinical-stage candidates that emphasize various therapeutic areas designed to address unmet medical needs. This includes focus on inflammatory diseases and cardiometabolic conditions, further solidifying their role in biotechnology advancements.

• Integrated R&D Services

  TransThera Sciences utilizes a fully integrated in-house research and development system to streamline the drug discovery and development process. This systematic approach fosters innovation and efficiency, which are essential for advancing therapeutic solutions in its focus areas.